MGMT and neoplasm: Subsequent workup and management are recommended by a multidisciplinary neuro-oncology tumor board that considers the GBM’s molecular characteristics, genetic variants, epigenetic modifications like MGMT methylation, immunohistochemical markers, and the patient’s post-operative functional status assessed by the Karnofsky Performance Scale (KPS) [5].